There is no doubt that the risk of invasive disease recurrence or death can be reduced by 50% among HER2-positive breast cancer patients with residual tumors who switch from HER2-directed therapy to the single agent T-DM1 (4). This evidence concerns the gene ERBB2 and breast cancer.